Inflammation and cardiovascular risk: An overview

International Journal of Angiology

Volumn 13, Issue 4, 2004, Pages 161-167

  Shammas, Nicolas W ^a,b   Dippel, Eric ^a  

^a MIDWEST CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^b Cardiovascular Medicine Davenport   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; AMYLOID A PROTEIN; ANTITHROMBOCYTIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD18 ANTIBODY; CELL ADHESION MOLECULE; COLONY STIMULATING FACTOR 1; CYTOKINE; EPTIFIBATIDE; FIBRINOGEN; FIBRINOGEN RECEPTOR ANTAGONIST; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; LIPID; LIPOPROTEIN A; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUTROPHIL CYTOPLASMIC ANTIBODY; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ACCURACY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DISEASE COURSE; GENETIC PREDISPOSITION; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; LIPID BLOOD LEVEL; MONOCYTE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; REVASCULARIZATION; REVIEW; RISK ASSESSMENT; UNSTABLE ANGINA PECTORIS; VASCULAR ENDOTHELIUM;

EID: 24644481419     PISSN: 10611711     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00547-004-1095-6     Document Type: Review

References (107)

1. S Kinlay AP Selwyn P Libby 1998 Inflammation, the endothelium, and the acute coronary syndromes J Cardiovasc Pharmacol 32 Suppl 3 S62 S66
2. S Verma TJ Andeson 2002 Fundamentals of endothelial function for the clinical cardiologist Circulation 105 546 549
3. HL Elliott 1998 Endothelial dysfunction in cardiovascular disease: risk factor, risk marker, or surrogate end point? J Cardiovasc Pharmacol 32 Suppl 3 S74 S77
4. R Ross JA Glomset 1973 Atherosclerosis and the arterial smooth muscle cell: proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis Science 180 1332 1339
5. P Libby PM Ridker A Maseri 2002 Inflammation and atherosclerosis Circulation 105 1135 1143
6. U Ikeda K Shimada 2003 Matrix metalloproteinases and coronary artery diseases Clin Cardiol 26 55 59
7. AC Newby AB Zaltsman 1999 Fibrous cap formation or destruction-the critical importance of vascular smooth muscle cell proliferation, migration and matrix formation Cardiovasc Res 41 345 360
8. M Bevilacqua RM Nelson 1993 Selectins J Chn Invest 91 379 387
9. GA Zimmerman SM Prescott TM McIntyre 1992 Endothelial cell interactions with granulocytes: tethering and signaling molecules Iumunol Today 13 93 100
10. YJ Shyy LL Wickham JP Hagan 1993 Human monocyte colony-stimulating factor stimulates the gene expression of monocyte chemotactic protein-1 and increases the adhesion of monocytes to endothelial monolayers J Clin Invest 92 1745 1751
11. U Ikeda K Matsui Y Murakami 2002 Monocyte chemoattractant protein-1 and coronary artery disease Clin Cardiol 25 143 147
12. ID Smith E Trogan M Ginsberg 1995 Decreased atherosclerosis in mice deficient in both macrophage colony stimulating factor (op) and apolipoprotein E Proc Natl Acad Sci USA 92 8264 8268
13. T Rajavashisth J-H Qiao J Tripathi 1998 Heterozygous osteopetrotic (op) mutation reduces atherosclerosis in LDL receptor-deficient mice J Clin Invest 101 2702 2710
14. EL Filonzi H Zoellner H Stanton 1993 Cytokine regulation of granulocyte-macrophage colony stimulating factor and macrophage-colony stimulating factor production in human arterial smooth muscle cells Atherosclerosis 99 241 252
15. H Zoellner EL Filonzi JA Hamilton 1992 Human arterial smooth muscle cells synthesize G-CSF in response to interleukin 1 alpha and tumor necrosis factor alpha Blood 80 2805 2810
16. S Fazio MF Linton 2001 The inflamed plaque: cytokine production and cellular cholesterol balance in the vessel wall Am J Cardiol 88 2A 12E 15E
17. TS Lee HC Yen CC Pan 1999 The role of interleukin 12 in the development of atherosclerosis in ApoE-deficient mice Arterioscler Thromb Vasc Biol 19 734 742
18. P Libby Y-J Geng M Aikawa 1996 Macrophages and atherosclerotic plaque stability Curr Opin Lipidol 7 330 335
19. P Libby 2001 Current concepts of the pathogenesis of the acute coronary syndromes Circulation 103 1718 1720
20. A Anwar AA Zahid KI Scheidegger 2002 Tumor necrosis factor-a regulates insulin-like growth factor-I and insulin-like growth factor binding protein-3 expression in vascular smooth muscle Circulation 105 1220 1225
21. CL Lendon MJ Davies GV Born 1991 Atherosclerotic plaque caps are locally weakened when macrophage density is increased Atherosclerosis 87 87 90
22. MJ Davies PD Richardson N Woolf 1993 Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content Br Heart J 69 377 381
23. PR Moreno E Falk IF Palacios 1994 Macrophage infiltration in acute coronary syndromes: implications for plaque rupture Circulation 90 775 778
24. N Malik BW Greenfield AE Wahl 1996 Activation of human monocytes through CD40 induces matrix metalloproteinases J Immunol 156 3952 3960
25. L Zhou P Stordeur A de Lavareille 1998 CD40 engagement on endothelial cells promotes tissue factor-dependent procoagulant activity Throm Haemost 79 1025 1028
26. DI Miller R Yaron MJ Yellin 1998 CD40L-CD40 interactions regulate endothelial cells surface tissue factor and thrombomodulin expression J Leukoc Biol 63 373 379
27. L Song C Leung C Schindler 2001 Lymphocytes are important in early atherosclerosis J Clin Invest 108 251 259
28. OJ de Boer AC van der Wal CE Verhagen 1999 Cytokine secretion profiles of cloned T cells from human aortic atherosclerotic plaques J Pathol 188 174 179
29. J Frostegard AK Ulfgren P Nyberg 1999 Cytokine expression in advanced human atherosclerotic plaques: dominance of proinflammation (Th1) and macrophage-stimulating cytokines Atherosclerosis 145 33 43
30. LM Biasucci G Liuzzo G Fontuzzi 1999 Increasing levels of interleukin (IL)-1 Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events Circulation 99 2079 2084
31. G Liuzzo A Buffon L Biasucci 1998 Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina Circulation 98 2370 2376
32. AM Lincoff DJ Kereiakes MA Mascelli 2001 Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization Circulation 104 163 167
33. G Morrone G Ciliberto S Oliviero 1988 Recombinant interleukin 6 regulates the transcriptional activation of a set of human acute phase gene J Biol Chem 263 12554 12558
34. U Ganter R Arcone C Toniatti 1989 Dual control of C-reactive protein gene expression by interleukin 1 and interleukin 6 EMBO J 8 3773 3779
35. DJ Rader 2000 Inflammation markers of coronary risk N Engl J Med 343 11179 1182
36. N Rifai PM Ridker 2001 High sensitivity C-reactive protein: a novel and promising marker of coronary heart disease Clin Chem 47 402 411
37. J Sarma CA Laan S Alam 2002 Increased platelet binding to circulating monocytes in acute coronary syndrome Circulation 105 2166 2171
38. J Kushner AR Sehgal 2002 Is high-sensitivity C-reactive protein an effective screening test for cardiovascular risk? Arch Intern Med 162 867 869
39. PM Ridker CH Hennekens JE Buring 2000 C-reactive protein and other markers of inflammation in the prediction of cardiovascular diseases in women N Engl J Med 342 836 843
40. PM Ridker NJ Brown DE Vaughan 2004 Established and emerging biomarkers in the prediction of first atheroembolic events Circulation 109 25 Suppl 1 IV6 IV19
41. KK Wu N Aleksic CM Ballantyne 2003 Interaction between soluble thrombomodulin and intercellular adhesion molecule-1 in predicting risk of coronary heart disease Circulation 107 1729 1732
42. S Blankenberg HJ Rupprecht O Poirier for the AtheroGene Investigators 2003 Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease Circulation 107 1579 1585
43. M Ridker 2003 Clinical application of C-reactive protein for cardiovascular disease and detection and prevention Circulation 107 363 369
44. P Libby PM Ridker 1999 Novel inflammatory markers of coronary risk. Theory versus practice Circulation 100 1148 1150
45. E Rossi LM Biasucci F Citterio 2002 Risk of myocardial infarction and angina in patients with severe peripheral vascular disease: predictive role of C-reactive protein Circulation 19 105 800 803
46. PM Ridker M Cushman MJ Stampfer 1997 Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men N Engl J Med 336 973 979
47. PM Ridker N Rifai L Rose 2002 Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events N Engl J Med 347 1557 1565
48. JR Downs M Clearfield S Weis 1998 Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS JAMA 279 1615 1622
49. PM Ridker N Rifai MA Pfeffer 1998 Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators Circulation 98 839 844
50. MA Albert E Danielson N Rifai PRINCE Investigators 2001 Effect of statin therapy on C-reactive protein levels. The Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study JAMA 286 64 70
51. DJ Lefer 2002 Statins as potent anti-inflammatory drugs Circulation 106 2041 2045
52. C Heeschen S Dimmeler CW Hamm for the Capture Study Investigators 2003 Soluble CD40 ligand in acute coronary syndromes N Engl J Med 384 1104 1111
53. SK James P Armstrong E Barnathan GUSTO-IV-ACS Investigators 2003 Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy J Am Coll Cardiol 41 916 924
54. JK Damas T Waehre A Yndestad 2003 Interleukin-7-mediated inflammation in unstable angina. Possible role of chemokines and platelets Circulation 107 2670 2676
55. P Aukrust F Muller T Ueland 1999 Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes Circulation 100 614 620
56. J Zhou M Chew HB Ravn 1999 Plaque pathology and coronary thrombosis in the pathogenesis of acute coronary syndromes Scand J Clin Lab Invest Suppl 230 3 11
57. JE Freedman J Loscalzo 2002 Platelet-monocyte aggregates. Bridging thrombosis and inflammation Circulation 105 2130 2132
58. RG McKay WE Boden 2001 Small peptide GP IIb/IIIa receptor inhibitors as upstream therapy in non-ST-segment elevation acute coronary syndromes: results of the PURSUIT, PRISM, PRISM-PLUS, TACTICS, and PARAGON trials Curr Opin Cardiol 16 364 369
59. MA Lauer PL Houghtaling JG Peterson Platelet IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Investigators 2001 Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptiflbatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial Circulation 104 2772 2777
60. Y Li FA Spencer S Ball 2000 Inhibition of platelet-dependent prothrombinase activity and thrombin generation by glycoprotein IIb/IIIa receptor-directed antagonists: potential contributing mechanism of benefit in acute coronary syndromes J Thromb Thrombolysis 10 69 76
61. M Levi T van der Poll 2004 Bidirectional relation between inflammation and coagulation Circulation 109 2698 2704
62. U Ikeda T Ito K Shimada 2001 Interleukin-6 and acute coronary syndromes Clin Cardiol 24 701 704
63. MS Sabatine DA Morrow JA de Lemos 2002 Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes. Simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide Circulation 105 1760 1763
64. C Mueller HJ Buettner JM Hodgson 2002 Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients Circulation 105 1412 1415
65. LM Biasucci G Liuzzo G Grillo 1999 Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability Circulation 99 855 860
66. A Lombardo LM Biasucci GA Lanza 2004 Inflammation as a possible link between coronary and carotid plaque instability Circulation 109 3158 3163
67. A Maseri V Fuster 2003 Is there a vulnerable plaque? Circulation 107 2068 2071
68. JF Keaney JM Massaro MG Larson 2004 Heritability and correlates of intercellular adhesion molecule-1 in the Framingham offspring study J Am Coll Cardiol 44 168 173
69. GH Gibbons CC Liew MQ Goodarzi 2004 Genetic markers: progress and potential for cardiovascular disease Circulation 109 25 Suppl 1 IV47 IV58
70. G Liuzzo A Buffon LM Biasucci 1998 Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina Circulation 98 2370 2376
71. P Santamaria RC Gehrz MV Bryan 1989 Involvement of class II MHC molecules in the LPS induction of IL-1/TNF secretions by human monocytes: quantitative differences at the polymorphic level J Immunol 143 913 922
72. I Ott F-J Neumann S Kenngott 1998 Procoagulant inflammatory responses of monocytes after direct balloon angioplasty in acute myocardial infarction Am J Cardiol 82 938 942
73. N Marx FJ Neumann I Ott 1997 Induction of cytokine expression in acute myocardial infarction J Am Coll Cardiol 30 165 170
74. T Inoue K Hoski I Yagushi 1999 Serum levels of circulating adhesion molecules after coronary angioplasty Cardiology 91 236 242
75. A Buffon G Liuzzo LM Biasucci 1999 Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty J Am Coll Cardiol 34 1512 1521
76. DP Chew DL Bhatt MA Robbins 2001 Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention Circulation 104 992 997
77. A Buffon LM Biasucci G Liuzzo 2002 Widespread coronary inflammation in unstable angina N Engl J Med 347 5 12
78. ETH Yeh V Anderson V Pasceri 2001 C-reactive protein. Linking inflammation to cardiovascular complications Circulation 104 974 975
79. I Ikonomidis F Andreotti E Economou 1999 Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin Circulation 100 793 798
80. S Goto K Eto Y Ikeda 1999 Abciximab not RGD peptide inhibits von Willebrand factor-dependent platelet activation under shear Lancet 353 9155 809
81. JK Mickelson MN Ali NS Kleiman 1999 Chimeric 7E3 Fab (ReoPro) decreases detectable CD 11b on neutrophils from patients undergoing coronary angioplasty J Am Coll Cardiol 33 1 97 106
82. U Kintscher K Kappert G Schmidt 2000 Effects of abciximab and tirofiban on vitronectin receptors in human endothelial and smooth muscle cells Eur J Pharmacol 390 1-2 75 87
83. DL Brown CS Farm CJ Chang 2001 Meta-analysis of effectiveness and safety of abciximab versus eptifibatide or tirofiban in percutaneous coronary intervention Am J Cardiol 87 5 537 541
84. SH Tam PM Sassoli RE Jordan 1998 Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha (v) beta3 integrins Circulation 98 1085 1091
85. DI Simon H Xu S Ortlepp 1997 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1 Arterioscler Thromb Vase Biol 17 528 535
86. MP Bendeck MT Nakada 2001 The beta3 integrin antagonist m7E3 reduces matrix metalloproteinase activity and smooth muscle cell migration J Vasc Res 38 6 590 599
87. U Kintscher K Kappert G Schmidt 2000 Effects of abciximab and tirofiban on vitronectin receptors in human endothelial and smooth muscle cells Eur J Pharmacol 390 1-2 75 87
88. FJ Neumann D Zohlnhofer L Fakhoury 1999 Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction J. Am Coll Cardiol 34 5 1420 1426
89. C Kupatt H Habazettl P Hanusch 2000 c7E3Fab reduces postischemic leukocyte-thrombocyte interaction mediated by fibrinogen. Implications for myocardial reperfusion injury Arterioscler Thromb Vase Biol 20 10 2226 2232
90. BS Coller 1999 Binding of abciximab to alpha V beta 3 and activated alpha M beta 2 receptors: with a review of platelet-leukocyte interactions Thromb Haemost 82 2 326 336
91. KM Anderson RM Califf GW Stone 2001 Long-term mortality benefits with abciximab in patients undergoing percutaneous coronary intervention J Am Coll Cardiol 37 2059 2065
92. JC O'Shea CE Buller WJ Cantor ESPRIT Investigators 2002 Long-term efficacy of platelet glycoprotein Ilb/IIIa integrin blockade with eptifibatide in coronary stent intervention JAMA 287 5 618 621
93. RM Scarborough 2002 Eptifibatide and 7E3, but not tirofiban, inhibit alpha(v)beta3 integrin-mediated binding of smooth muscle cells to thrombospondin and prothrombin Circulation 105 6 e46
94. A Merino Otermin M Artaiz Urdaci J Bergada Garcia 2002 Eptifibatide blocks the increase in C-reactive protein concentration after coronary angioplasty Rev Esp Cardiol 55 2 186 189
95. FGP Welt SD Rogers X Zhang 2004 Gp2b/3a inhibition with eptifibatide lowers levels of soluble CD40L and RANTES after percutaneous coronary intervention Catheter Cardiovasc Ihterv 61 185 189
96. Shammas NW, Dippel EJ, Robken J, et al. (2004) integrilin reduces CD-40L acutely in patients undergoing peripheral vascular interventions: Results of the INFLAME trial [abstract]. Presented at the 4th Annual New Cardiovascular Horizons (NCVH), October 14-16 New Orleans, Louisiana
97. JK Plenge TL Hernandez KM Weil 2002 Simvastatin lowers C-reactive protein within 14 days. An effect independent of low-density lipoprotein cholesterol reduction Circulation 106 1447 1452
98. T Waehre A Yndestad C Smith 2004 Increased expression of interleukin-1 in coronary artery disease with downregulation effects of HMG-CoA reductase inhibitors Circulation 109 1966 1972
99. F Mach 2004 statins as immunomodulatory agents Circulation 109 21 Suppl 1 II15 II17
100. MB Shishehbor M-L Brennan RJ Aviles 2003 Statins promote potent systemic antioxidant effects through specific oxidation pathways Circulation 108 426 431
101. R Corti V Fuster ZA Fayad 2002 Lipid lowering by simvastatin induces regression of human atherosclerotic lesions. Two years' follow-up by high-resolution non-invasive magnetic resonance imaging Circulation 106 2884 2887
102. RS Wright JG Murphy KA Bybee 2002 Statin lipid-lowering therapy for acute myocardial infarction and unstable angina: efficacy and mechanism of benefit Mayo Clin Proc 77 1085 1092
103. J Herrmann A Lerman D Baumgart 2002 Preprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarction Circulation 106 2180 2183
104. M Eto T Kozai F Cosentino 2002 Statin prevents tissue factor expression in human endothelial cells. Role of Rho/Rho-kinase and Akt pathways Circulation 105 1756 1759
105. KW Baran M Nguyen GR McKendall LIMIT-AMI Investigators 2001 Double blind, randomized trial of an anti-CD 18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction Circulation 104 2778 2783
106. M Aran DJ Lefer T So 1996 An anti-CD18 antibody limits infarct size and preserves left ventricular function in dogs with ischemia and 48-hour reperfusion J Am Coll Cardiol 27 1278 1285
107. T Aversano W Zhou M Nedelman 1995 A chimeric IgG4 monoclonal antibody directed against CD18 reduces infarct size in a primate model of myocardial ischemia and reperfusion J Am Coll Cardiol 25 781 788